Genelex CLIA DNA Test Approved by New York | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genelex today said that New York state has approved its CLIA-based DNA Drug Sensitivity Tests for the testing of three enzymes involved in drug metabolism.

The approval means Genelex's CLIA lab has regulatory approval to test patient samples from every state in the US, "a critical milestone for Genelex," the company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.